Peptide Research Hub
Educational reference
Educational reference only. Nothing on this site is medical advice. Many compounds described here are not FDA-approved, lack adequate human evidence, and may be illegal in your jurisdiction. Always consult a licensed clinician.

Metabolic & GLP-1/GIP Agonists

Cagrilintide

Evidence: Moderate clinical Disclaimer: Critical Investigational

Mechanism & research context

Long-acting amylin analog studied in Phase 3 development, typically in combination with semaglutide (CagriSema).

Safety flags

0 flags

No curator-recorded safety flags for this entry. Absence of recorded flags is not evidence of safety. Many peptides lack adequate human data.

Research papers

16 records

Citation links route to PubMed, Europe PMC, and PMC. Presence of a study is not endorsement. Records are refreshed from PubMed on a regular cadence; rows marked “Live search link” will resolve to a current PubMed search until a full citation has been ingested.

Clinical trials

21 records
  • Live search Live search

    Live ClinicalTrials.gov search: Cagrilintide

    Condition: See live results

    Open on ClinicalTrials.gov ↗
  • NCT03856047 PHASE2 COMPLETED

    Investigation of Safety and Efficacy of NNC0174-0833 for Weight Management - a Dose Finding Trial.

    Condition: Overweight; Obesity

    Sponsor: Novo Nordisk A/S

    Open on ClinicalTrials.gov ↗
  • NCT04982575 PHASE2 COMPLETED

    Efficacy and Safety of Co-administration of Cagrilintide s.c. 2.4 mg and Semaglutide s.c. 2.4 mg Once Weekly in Subjects With Type 2 Diabetes

    Condition: Diabetes Mellitus, Type 2

    Sponsor: Novo Nordisk A/S

    Open on ClinicalTrials.gov ↗
  • NCT05394519 PHASE3 COMPLETED

    Efficacy and Safety of Cagrilintide s.c. 2.4 mg in Combination With Semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly in Participants With Overweight or Obesity and Type 2 Diabetes

    Condition: Overweight; Obesity; Type 2 Diabetes Mellitus

    Sponsor: Novo Nordisk A/S

    Open on ClinicalTrials.gov ↗
  • NCT05564104 PHASE1 COMPLETED

    A Study Investigating the Pharmacokinetic Properties of Cagrilintide in Participants With Various Degrees of Hepatic Impairment and Assessing the Absolute Bioavailability of Subcutaneous Cagrilintide in Healthy Volunteers

    Condition: Hepatic Impairment; Healthy Volunteers

    Sponsor: Novo Nordisk A/S

    Open on ClinicalTrials.gov ↗
  • NCT05567796 PHASE3 ACTIVE_NOT_RECRUITING

    Efficacy and Safety of Cagrilintide s.c. 2.4 Milligram (mg) in Combination With Semaglutide Subcutaneous (s.c). 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly in Participants With Overweight or Obesity

    Condition: Obesity

    Sponsor: Novo Nordisk A/S

    Open on ClinicalTrials.gov ↗
  • NCT05669755 PHASE3 ACTIVE_NOT_RECRUITING

    The Cardiovascular Safety and Efficacy of Cagrilintide 2.4 mg s.c. in Combination With Semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) Once-weekly in Participants With Established Cardiovascular Disease

    Condition: Cardiovascular Disease

    Sponsor: Novo Nordisk A/S

    Open on ClinicalTrials.gov ↗
  • NCT05804162 PHASE1 COMPLETED

    A Thorough QTc Study Evaluating the Effect of Cagrilintide on Cardiac Repolarisation in Healthy Participants

    Condition: Obesity

    Sponsor: Novo Nordisk A/S

    Open on ClinicalTrials.gov ↗
  • NCT05813925 PHASE3 COMPLETED

    Efficacy and Safety of Cagrilintide S.C. 2.4 mg in Combination With Semaglutide S.C. 2.4 mg (CagriSema S.C. 2.4 mg/2.4 mg) Once-Weekly in East Asian Participants With Overweight or Obesity

    Condition: Obesity or Overweight

    Sponsor: Novo Nordisk A/S

    Open on ClinicalTrials.gov ↗
  • NCT06065540 PHASE3 COMPLETED

    Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) s.c. in Doses 2.4/2.4 mg and 1.0/1.0 mg Once Weekly Versus Semaglutide 2.4 mg and 1.0 mg, Cagrilintide 2.4 mg and Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Metformin With or Without an SGLT2 Inhibitor

    Condition: Type 2 Diabetes Mellitus

    Sponsor: Novo Nordisk A/S

    Open on ClinicalTrials.gov ↗
  • NCT06131372 PHASE2 COMPLETED

    Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema 2.4 mg/2.4 mg) Once Weekly Versus Semaglutide 2.4 mg, Cagrilintide 2.4 mg and Placebo in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity

    Condition: Chronic Kidney Disease; Type 2 Diabetes; Obesity

    Sponsor: Novo Nordisk A/S

    Open on ClinicalTrials.gov ↗
  • NCT06289504 PHASE1 COMPLETED

    An Open-label, One-sequence Cross-over, Single-centre Trial, Investigating the Influence of CagriSema on Pharmacokinetics and Pharmacodynamics of Warfarin and Pharmacokinetics of Atorvastatin in Participants With Overweight or Obesity

    Condition: Obesity

    Sponsor: Novo Nordisk A/S

    Open on ClinicalTrials.gov ↗
  • NCT06323161 PHASE3 COMPLETED

    Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) s.c. in Doses 2.4 mg/2.4 mg and 1.0 mg/1.0 mg Once Weekly Versus Placebo in Participants With Type 2 Diabetes as Add on to Once-daily Basal Insulin With or Without Metformin

    Condition: Type 2 Diabetes

    Sponsor: Novo Nordisk A/S

    Open on ClinicalTrials.gov ↗
  • NCT06323174 PHASE3 COMPLETED

    Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) s.c. in Doses 2.4 mg/2.4 mg and 1.0 mg/1.0 mg Once Weekly Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Diet and Exercise

    Condition: Type 2 Diabetes

    Sponsor: Novo Nordisk A/S

    Open on ClinicalTrials.gov ↗
  • NCT06388187 PHASE3 COMPLETED

    Efficacy and Safety of Cagrilintide s.c. in Combination With Semaglutide s.c.(CagriSema s.c. 1.0 mg/1.0 mg and 1.7 mg/1.7 mg) Once-weekly in Participants With Overweight or Obesity

    Condition: Obesity

    Sponsor: Novo Nordisk A/S

    Open on ClinicalTrials.gov ↗
  • NCT06403761 PHASE1 COMPLETED

    Effect of CagriSema, Semaglutide and Cagrilintide on Insulin Sensitivity and Pancreatic Endocrine Function in Adults With Type 2 Diabetes

    Condition: Diabetes Mellitus, Type 2

    Sponsor: Novo Nordisk A/S

    Open on ClinicalTrials.gov ↗
  • NCT06409130 PHASE2 COMPLETED

    Effects of NNC0194-0499 Alone and in Combination With Semaglutide, of Semaglutide Alone, and of Cagrilintide Alone and in Combination With Semaglutide on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease

    Condition: Alcohol-related Liver Disease

    Sponsor: Novo Nordisk A/S

    Open on ClinicalTrials.gov ↗
  • NCT07184086 PHASE1 RECRUITING

    The Effect of Cagrilintide and Semaglutide Combination Treatment Compared to a Weight-loss Inducing Diet on Energy Metabolism in Persons Living With Obesity: an Open-label Randomised Study

    Condition: Obesity

    Sponsor: Novo Nordisk A/S

    Open on ClinicalTrials.gov ↗
  • NCT07357740 PHASE2 NOT_YET_RECRUITING

    A Phase 2 Study to Compare Two Presentations of CagriSema in Participants With Type 2 Diabetes

    Condition: Diabetes Mellitus, Type 2

    Sponsor: Novo Nordisk A/S

    Open on ClinicalTrials.gov ↗
  • NCT07357766 PHASE3 NOT_YET_RECRUITING

    A Placebo-controlled Comparability Study to Compare Two Presentations of CagriSema in Participants With Overweight or Obesity

    Condition: Overweight; Obesity

    Sponsor: Novo Nordisk A/S

    Open on ClinicalTrials.gov ↗
  • NCT07411560 PHASE1 RECRUITING

    Single-centre Study Investigating the Role of Long-acting Subcutaneous Glucose-dependent Insulinotropic Polypeptide Receptor Agonist (GIP RA) in Combination With Long-acting Subcutaneous Amylin Receptor Agonist on Gastrointestinal Tolerability in Participants With Overweight or Obesity

    Condition: Overweight; Obese

    Sponsor: Novo Nordisk A/S

    Open on ClinicalTrials.gov ↗

Doses reported in studies

0 records
This is not a dosing guide. Entries below are historical metadata transcribed verbatim from a cited clinical-trial protocol, published study, or FDA-approved label. They describe what was administered in a specific study population under medical supervision — they are not recommendations, not common-use guidance, and may not be safe or appropriate outside the cited context. Doses widely discussed in community/anecdotal sources are not shown here; see the safety policy for why.

No study-protocol dose records have been curated for Cagrilintide yet. Absence of records is not evidence of safety — many peptides lack adequate human-trial data in the first place.

Records here are populated from public sources only (ClinicalTrials.gov protocol summaries and FDA-approved labels) and must cite a verifiable source URL. They are not added from forum posts, vendor pages, anecdotal write-ups, or social media.

These entries describe what was studied. They do not tell you what to take, how to reconstitute anything, how to fill a capsule, how often to administer, or where to obtain a compound. If you are considering use of Cagrilintide, those decisions belong with a licensed clinician working from the full label or trial record — not from this summary.

Why this page does not list a dose for self-use

The "Doses reported in studies" section above (when populated) describes what was administered in a cited study or label, under medical supervision, in a specific population. It is not a dosing guide for self-use. Separately, we do not publish anecdotal or community-reported dose ranges, administration methods, vial concentrations, or capsule masses for Cagrilintide. Anecdotal figures for unapproved compounds are not harm-reduction data: they lack denominators for adverse events, cannot account for individual physiology or compound purity, and normalise unsupervised use. See the safety policy for the full reasoning.

If this compound has an FDA-approved label

If a label exists, the regulator-reviewed dosing and administration information is there — read it in the context of a prescriber's evaluation.

Questions worth bringing to a clinician

  • What is the evidence for this compound in someone with my history?
  • What are the realistic, regulator-reviewed alternatives?
  • What would you monitor, and what would make you stop?

If you have already taken a peptide and feel unwell: contact emergency services. In the United States, Poison Control is reachable 24/7 at 1-800-222-1222. Do not wait for a community thread.

Research peptides are not substitutes for medical care. If you are considering any peptide for health purposes, speak with a board-certified physician or endocrinologist first.